GHK-Cu (copper peptide): compounding status, evidence and risks
As of October 15, 2026, GHK-Cu has no FDA-approved drug product, and its compounding status depends on the route: non-injectable GHK-Cu is in Category 1 of FDA’s interim 503A policy, while injectable GHK-Cu sits in no category after its nomination was withdrawn in April 2026. FDA plans to ask its advisory committee about GHK-Cu before the end of February 2027.
Status at a glance
| Check | Status as of October 15, 2026 | Source · read date |
|---|---|---|
| FDA approval | No FDA-approved drug product found. | FDA · read October 15, 2026 |
| 503A interim category | Split by route. Non-injectable: Category 1 (“GHK-Cu (except for injectable routes of administration)”), categories PDF updated May 14, 2026. Injectable: nominated but withdrawn from Category 2 (page current as of April 22, 2026), now in no category. | FDA · read October 15, 2026; FDA withdrawn list |
| FDA advisory committee (PCAC) | Not voted in July 2026. FDA “intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027.” | FDA · read October 15, 2026 |
| WADA 2026 Prohibited List | Not named on the 2026 list text we read; no classification found. S0 covers unapproved substances not listed elsewhere, so athletes should ask their anti-doping body. | World Anti-Doping Agency · read October 15, 2026 |
| FDA warning letters, 2026 | None found. | FDA warning letters · read October 15, 2026 |
| WADA 2027 list | Not named on the 2027 list (in force January 1, 2027). The 2027 S0 class now names “peptides” among its examples of non-approved substances. | World Anti-Doping Agency · read October 15, 2026 |
Why the route matters
FDA’s categories PDF records an unusual sequence. GHK-Cu (for non-injectable routes) “was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators.” On May 5, 2026, one nominator clarified that it meant to withdraw only the injectable route, and FDA said non-injectable GHK-Cu “will be added back to category 1” (FDA PDF).
The practical result: a licensed 503A pharmacy may compound non-injectable GHK-Cu (for example a topical preparation) under FDA’s Category 1 enforcement discretion, but injectable GHK-Cu has no such cover. Category 1 is not approval. It means FDA does not intend to take action against licensed pharmacies for compounding with the substance while it evaluates it.
Human evidence
We did not find controlled human trials of injected GHK-Cu that we could cite, and we have not re-read the skin-care literature for this update. We therefore make no claim about what GHK-Cu does in people, by any route.
Animal and laboratory evidence
Much of the interest in GHK-Cu comes from laboratory and animal research on wound healing and skin. Those studies are not evidence that an injection or cream will produce the same effect in you.
Risks
FDA’s concern centres on injection: “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” (FDA).
Legal sourcing: who can supply it
A prescription for non-injectable GHK-Cu, filled by a licensed 503A pharmacy, falls within FDA’s Category 1 policy. A prescription for injectable GHK-Cu does not, as of October 15, 2026. Ask the clinic which route it is prescribing and which pharmacy compounds it. See how to verify a peptide provider.
The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For GHK-Cu: the April withdrawal briefly removed it from Category 1 entirely; non-injectable GHK-Cu was restored after the May 5 clarification. It was not on the July PCAC agenda. Whether the interim access policy covers injectable GHK-Cu is not known. See the legality guide.
Frequently asked questions
Is GHK-Cu legal to compound?
It depends on the route. As of October 15, 2026, non-injectable GHK-Cu is in Category 1 of FDA’s interim 503A policy, so licensed pharmacies may compound it under enforcement discretion. Injectable GHK-Cu is in no category after its nomination was withdrawn in April 2026.
Is GHK-Cu FDA-approved?
No. We found no FDA-approved drug product containing GHK-Cu. Category 1 status for non-injectable forms is enforcement discretion while FDA evaluates the substance, not approval, and it says nothing about whether GHK-Cu works.
Why is injectable GHK-Cu treated differently?
FDA says compounded injectable GHK-Cu may cause immune reactions because of aggregation and peptide-related impurities. A nominator also withdrew only the injectable route in May 2026, which left injectable GHK-Cu outside every interim category.
When will FDA decide on GHK-Cu?
FDA says it intends to consult its Pharmacy Compounding Advisory Committee about adding GHK-Cu to the 503A bulks list before the end of February 2027. No date had been announced as of October 15, 2026.
New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).
Sources
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current as of April 22, 2026) (read October 15, 2026)
- FDA — Bulk drug substances used in compounding under section 503A (page current as of May 14, 2026) (read October 15, 2026)
- McDermott Will & Schulte — PCAC backs majority of peptides in two-day public meeting (July 27, 2026; reported vote counts) (read October 15, 2026)
- World Anti-Doping Agency — Prohibited List (2026 list in force) (read October 15, 2026)
- OIRA (reginfo.gov) — Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94 (pending EO 12866 review) (read October 15, 2026)
- Reuters via Yahoo News — FDA takes step to change peptide compounding access (October 15, 2026) (read October 15, 2026)
- World Anti-Doping Agency — 2027 Prohibited List (published September 21, 2026; in force January 1, 2027) (read October 15, 2026)